1. Home
  2. DTST vs INTS Comparison

DTST vs INTS Comparison

Compare DTST & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Data Storage Corporation

DTST

Data Storage Corporation

HOLD

Current Price

$3.74

Market Cap

8.5M

Sector

Technology

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.55

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTST
INTS
Founded
2001
2012
Country
United States
United States
Employees
55
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DTST
INTS
Price
$3.74
$4.55
Analyst Decision
Hold
Buy
Analyst Count
1
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
38.4K
22.9K
Earning Date
04-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.39
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$0.19
52 Week High
$5.44
$8.06

Technical Indicators

Market Signals
Indicator
DTST
INTS
Relative Strength Index (RSI) 39.79 32.71
Support Level N/A $4.50
Resistance Level $4.34 $8.06
Average True Range (ATR) 0.25 0.20
MACD -0.06 -0.01
Stochastic Oscillator 7.22 10.31

Price Performance

Historical Comparison
DTST
INTS

About DTST Data Storage Corporation

Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: